key: cord-0937842-jgfwwi68
authors: Singh, Abhishek; Khanna, Puneet; Sarkar, Soumya
title: High-Flow Nasal Cannula, a Boon or a Bane for COVID-19 Patients? An Evidence-Based Review
date: 2021-03-02
journal: Curr Anesthesiol Rep
DOI: 10.1007/s40140-021-00439-4
sha: 8e244627a793ef319810e74f6c26836f57ffdcae
doc_id: 937842
cord_uid: jgfwwi68

PURPOSE OF REVIEW: This review instantiates the efficacy and safety of HFNC in the context of COVID-19 pandemic. RECENT FINDINGS: Globally, the healthcare system is facing an unprecedented crisis of resources due to the 2019 novel coronavirus disease (COVID-19) pandemic. Fever, cough, dyspnea, myalgia, fatigue, and pneumonia are the most common symptoms associated with it. The incidence of invasive mechanical ventilation in ICU patients ranges from 29.1 to 89.9%. Supplemental oxygen therapy is the main stay treatment for managing hypoxemic respiratory failure. The high-flow nasal cannula (HFNC) is a novel non-invasive strategy for better oxygenation and ventilation in critically ill patients. In this grim scenario, a reduction in mechanical ventilation by means of HFNC is of prime interest SUMMARY: HFNC is considered an aerosol-generating intervention with the risk of viral aerosolization with a concern of potential nosocomial transmission of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). However, there is no consensus regarding the use of HFNC in novel coronavirus-infected pneumonia (NCIP). HFNC seems to be an effective and safe treatment modality in acute respiratory failure with optimal settings and selection of ideal patients.

The 2019 novel coronavirus disease , caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), is the burning issue worldwide with an unprecedented crisis in healthcare systems. Fever, cough, dyspnea, myalgia, fatigue, and radiological corroboration of pneumonia are the most common symptoms associated with it. Acute respiratory infection due to COVID-19 is termed as novel coronavirus-infected pneumonia (NCIP) [1] . The initial reports from China indicate severe clinical conditions in 14% of patients, and intensive care is required in 5% of patients [2] . The incidence of invasive mechanical ventilation in ICU patients ranges from 29.1 to 89.9% [3] .

Supplemental oxygen is the cornerstone for managing hypoxemic respiratory failure. The use of a nasal cannula, bag valve masks, non-rebreathing masks, or any other low flow devices prompts entrainment of room air as the inspiratory flow rates in quiet breathing (30 L/min) surmounts the possible maximum supplemental oxygen flow of these devices (15 L/min), resulting in limiting the delivered FiO 2 during respiratory distress (>100 L/min) [4] .

The high-flow nasal cannula (HFNC), delivering 60 L/min warm, humidified oxygen with precise titration of FiO2 through nasal prongs, has emerged as a popular noninvasive strategy for better oxygenation and ventilation in critically ill patients by prevailing over the flow limitation of the low flow devices [5] .

HFNC has been found to be beneficial for avoiding intubation in acute hypoxaemic respiratory failure patients in comparison with conventional oxygen devices. However, the majority of the studies are not in the context of COVID-19 pandemic, and bio-aerosol dispersion due to the high gas flow is a serious concern. Thus, the aim of this review is to address the efficacy and safety of HFNC in COVID-19.

HFNC provides a flow-dependent FiO 2 by reducing room air entrainment through a greater flow than inspiratory demand ( Fig. 1) [7] . An increase in flow from 15 to 45 L/min results into a subsequent rise in FiO 2 from 0.60 to 0.90 [8] .

It reduces the work of breathing by washing out the carbon dioxide (CO 2 ) from the upper airways, thereby diminishing the anatomical dead space [9] . The anatomic dead space is found to be reduced significantly from 20 to 60 cc with a concomitant increase in flow from 15 to 45 L/min [10] .

HFNC ensures better mucociliary clearance by proving heated and humidified oxygen. The optimally conditioned oxygen reduces the work of breathing also and provides better conductance and compliance in comparison with dry and cooler one. [11, 12] It also provides low-level positive pressure. A flow of 50 L/min provides a mean airway pressure between 1.7 cm H 2 O (mouth open) and 3.3 cm H 2 O (mouth closed) [13] . The increase in end-expiratory lung volumes provides better alveolar recruitment and thereby reduces the risk of atelectasis and improves the oxygenation. However, as most of the patients in respiratory distress tend to breathe with an open mouth, the effect may not be evident [14] .

In comparison with non-invasive ventilation (NIV), the oral intake, and toileting of secretions, communication is not hindered with HFNC [6] .

The SARS-CoV-2 virus is mediated by angiotensinconverting enzyme 2 (ACE2) receptor, which is abundantly expressed in the alveolar epithelial cells [15, 16] . Initially, the virus replicates in the epithelium of the upper airways. With further multiplication, it infiltrates the pulmonary parenchyma, causing an inflammatory response by means of vasodilation, increased endothelial permeability, and leukocyte recruitment, resulting in focal pneumonia and thereby hypoxemia [17] .

At present, two types of NCIP are recognized. The L type presents with a lower lung elastance along with normal lung compliance. On the contrary, The H type manifests as classic ARDS with, low compliance, increased extravascular lung water, and high elasticity [18, 19] .

The HFNC has a potential role for reducing the requirement of intubation in both the phenotypes, preferentially in L type as it is capable to meet the higher oxygen demand by means of providing heated and humidified oxygen 21 to 100% up to 60 L/min [6] .

HFNC undoubtedly has better patient compliance [20] . In comparison with NIV for providing a tidal volume of 7 to 10 mL/kg, the use of HFNC (50 L/min; Fio 2 , 100%) in patients with PaO 2 /FIO 2 < 200 results has been associated with lower intubation rate (50%, 38%, respectively) and mortality rate (49%, 30%, respectively) [21] . [6] HFNC is found to be non-inferior to NIV for reintubation in patients after cardiac surgery [22] as well as extubation after acute respiratory failure [23] .

A recent systematic review has reported that HFNC may reduce the requirement of mechanical ventilation in comparison with conventional oxygen therapy (RR, 0.71; 95% CI 0.51 to 0.98; I 2 = 52%) with a potential risk of airborne transmission. However, the included studies are not providing direct evidence regarding COVID-19 [ Globally, the COVID-19-related respiratory failure is constraining the ICU resources and mechanical ventilators. In this grim scenario, a reduction in mechanical ventilation by means of HFNC is of prime interest with a potential risk [29] Retrospective Observational study 33 17 -16 Zhou F et al,2020 [30] Retrospective cohort study 41 8 -33 Liao X et al., 2020 [31] Retrospective Observational study 31 25 -6 Luo X et al., 2020 [32] Retrospective Observational study 106 32 -74

HFNC High-flow nasal cannula, NIV non-invasive ventilation, IV invasive ventilation [35] HFNC Suggest AIPO (Italy) [36] H e l m e t C P A P -CTS (China) [37] HFNC Pro ESICM/SCCM (EU/US) [38] HFNC Pro German recommendations for critically ill patients with COVID-19 (Germany) [39] Helmet NIV Restricted Irish Thoracic Society, (Ireland) [33] HFNC Pro National Healthcare System Guidelines, (UK) [40] CPAP HFNC contra indicated, no benefit but risk SEPAR (Spain) [41] HFNC Maintain > 2-m distance SPP (Portugal) [ 

At present, there is no consensus regarding the use of HFNC in NCIP across the eminent organizations ( Table 2 ). In view of potential aerosol-generating modality, some guidelines are skeptical about it. Some institutions strongly favor early intubation in view of the suspected high failure rate of non-invasive approaches in COVID-19 that often lands in to crash intubation, Additionally, the non-invasive approaches help in avoiding unnecessary intubations and well-known aerosol generators thereby protecting the staff and ensuring optimal utilization of resources [33, 34] . The WHO guidelines advocate for HFNC prior to intubation in the overall plan of management [43••] . Similarly, the surviving sepsis guidelines of SCCM also recommend for HFNC over non-invasive ventilation during conventional oxygen therapy failure [38] .

HFNC is considered an aerosol-generating intervention with the risk of viral aerosolization. The dispersion is maximum at 60 L/min; however, the smoke dispersion distance from the manikin is similar to a simple oxygen mask at 15 L/min [44] .

The use of a proper fitting nasal cannula, along with a droplet mask placed over the nasal interface with a high limit of 30-40 L/min, preferably in a negativepressure room is beneficial for reducing the risk of dispersion of aerosol [6, 45••] .

The application of HFNC demands vigilant monitoring as unanticipated intubation bears an increased risk of aerosol exposure. Tachypnoea, tachycardia, inadequate oxygenation despite a high-flow rate, altered sensorium, and hypercarbia are the signs of impending failure. Roca et al. [46••] suggested that a high specificity for ROX score < 3.85 at 12 h is associated with failure.

HFNC is an easy and safe treatment modality in acute respiratory failure with multiple physiological benefits. However, further studies regarding optimal settings, initiation, selection of patients, and duration of therapy are the need of the hour.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Mechanical ventilation in COVID-19: interpreting the current epidemiology

High-flow nasal cannula oxygen in adults: an evidencebased assessment

High-flow oxygen therapy in acute respiratory failure

High flow nasal cannula -COVID 19 and beyond

Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study

Comparison of three high flow oxygen therapy delivery devices: a clinical physiological cross-over study

Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure

Nasal high flow reduces dead space

Discomfort associated with under humidified high-flow oxygen therapy in critically ill patients

The effects of gas humidification with high-flow nasal cannula on cultured human airway epithelial cells

The effects of flow on airway pressure during nasal high-flow oxygen therapy

Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients

A novel angiotensin converting enzyme related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

COVID-19, ACE2, and the cardiovascular consequences

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

COVID-19 pneumonia: different respiratory treatments for different phenotypes?

Covid-19 does not lead to a "typical" acute respiratory distress syndrome

Heated humidified highflow nasal oxygen in adults: mechanisms of action and clinical implications

High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure

BiPOP Study Group. Highflow nasal oxygen vs noninvasive positive airway pressure in hypoxemic patients after cardiothoracic surgery: a randomized clinical trial

Effect of post extubation high-flow nasal cannula vs non-invasive ventilation on reintubation and post extubation respiratory failure in high-risk patients: a randomized clinical trial

Les canules nasales à haut débit pour le traitement de l'insuffisance respiratoire hypoxémique aiguë chez les patients atteints de la COVID-19: comptes rendus systématiques de l'efficacité et des risques d'aérosolisation, de dispersion et de transmission de l'infection

The experience of highflow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing

Application of high-flow nasal cannula in hypoxemic patients with COVID-19: a retrospective cohort study

Clinical course and outcomes of 344 intensive care patients with COVID-19

High flow nasal cannula is a good treatment option for COVID-19. Heart Lung

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Critical care for severe COVID-19: a population-based study from a province with low case-fatality rate in China

Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China

High-flow, noninvasive ventilation and awake (nonintubation) proning in patients with COVID-2019 with respiratory failure

COVID-19 pandemic and non invasive respiratory management: every Goliath needs a David. An evidence based evaluation of problems

Australian and New Zealand Intensive Care Society

Managing the respiratory care of patients with COVID-19

Respiratory care committee of Chinese Thoracic S. Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia

Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)

Recommendations for critically ill patients with COVID-19

Guidance for the role and use of non-invasive respiratory support in adult patients with COVID19

Version 3

Recomendaciones deconsenso respecto al soporte respiratorio no invasivo en el paciente adulto con insuficiencia respiratoria aguda secundaria a infección por SARSCoV-2

Terapias respiratória não invasivas em contexto de doente agudo/crónico agudizadona COVID-19

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance

Exhaled air dispersion during highflow nasal cannula therapy versus CPAP via different masks

High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion

An index combining respiratory rate and oxygenation to predict outcome of nasal high flow therapy

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations